Aligned with preceding studies, our research discovered that Salvigenin hindered the activity of the PI3K/AKT/GSK-3β pathway, thus impeding HCC cell aerobic glycolysis and chemoresistance. The gene discussed is AKT1; the disease is hepatocellular carcinoma.